We found that combined inhibition of the Rb transcriptional repressor and the FZR1 APC/C co-activator eliminates the normal requirement for CDK4/6-cyclin D kinase activity in C. elegans and human breast cancer cells. Here, CDK4 is linked to breast cancer.